Drug Trial Radar · NCT06132256
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Dec 11, 2023
Primary completion
Aug 27, 2026
Study completion Sep 10, 2026
Sponsor
- Lead sponsor
- Syndax PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- DevPro Biopharma
- First posted
- Nov 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy and safety of axatilimab in participants with IPF.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
AxatilimabDrug
Administered as intravenous (IV) infusion
PlaceboOther
Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of decline in morning pre-dose trough forced vital capacity (FVC) (milliliter [mL])Time frame: Baseline through Week 26
Locations
78 sites in 13 countries. Site status is shown where the registry gives one.
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Wallace Street Specialist Centre
Brisbane, Queensland, Australia
Mater Misericordiae Ltd
South Brisbane, Queensland, Australia
Griffith University Clinical Trial Unit
Southport, Queensland, Australia
Mackay Hospital & Health Service
West Mackay, Queensland, Australia
Monash Health
Clayton, Victoria, Australia
Institute for Respiratory Health
Perth, Western Australia, Australia
OLV Hospital Aalst
Aalst, Oost-Vlaanderen, Belgium
AZ Groeninge
Kortrijk, West-Vlaanderen, Belgium
Dynamic Drug Advancement
Ajax, Canada
Centre de Recherche Clinique - CHUS
Sherbrooke, Quebec, Canada
Thomayer University Hospital
Prague, Czechia
CHU Amiens
Amiens, France
Chu Brest
Brest, France
CHU Dijon
Dijon, France
CHU de Rennes
Rennes, France
Klinikum Chemnitz - Zentrum für klinische Studien
Chemnitz, Germany
Studienzentrum Dr. Keller
Frankfurt am Main, Germany
Asklepios Lungenklinik Gauting
Gauting, Germany
RoMed Klinikum Rosenheim
Rosenheim, Germany
Klinikum Konstanz, Innere Medizin, Pneumologie
Konstanz, Baden-Wurttemberg, Germany
Pneumologisches Studienzentrum München-West
Munich, Bavaria, Germany
Medizinische Hochschule Hannover
Hanover, Lower Saxony, Germany
A.O.U. Policlinico "G. Rodolico - San Marco"
Catania, Italy
Azienda Ospedaliero Universitaria di Careggi
Florence, Italy
AOU di Modena
Modena, Italy
AOU Città della Salute e della Scienza di Torino - Molinette
Molinette, Italy
ISMETT
Palermo, Italy
Ospedale Colonnello D'Avanzo
Foggia, Apulia, Italy
ASST Santi Paolo e Carlo
Milan, Lombardy, Italy
San Gerardo
Monza, MB, Italy
Azienda Ospedaliera Universitaria San Luigi Gonzaga
Torino, Orbassano, Italy
University of Padua
Padova, Padua, Italy
Azienda Ospedaliera Universitaria Senese
Siena, Tuscany, Italy
Mics Centrum Medyczne Bydgoszcz
Bydgoszcz, Poland
Makowskie Centrum medyczne Hamernia Sp zz
Maków Podhalański, Poland
Warmia and Mazury Center for Lung Diseases
Olsztyn, Poland
Vitamed Galaj I Cichomski sp.j.
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Clinica Lavinia Davidescu SRL
Oradea, Romania
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.